Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT04042727

Controlling Rapid Atrial Fibrillation With Dexmedetomidine (C-RAD)

Controlling Rapid Atrial Fibrillation With Dexmedetomidine (C-RAD) Trial

Sponsor: Stony Brook University

Conditions Heart Rate Control Rapid Atrial Fibrillation

Interventions Dexmedetomidine Hydrochloride Normal Saline

Updated 6 times since 2019 Last updated: Jun 1, 2024 Started: Aug 21, 2019 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Futility, as a result of COVID-19 impact

Other terminated trials from Stony Brook University

See all terminations from Stony Brook University

Listed as NCT04042727, this PHASE2/PHASE3 trial focuses on Heart Rate Control and Rapid Atrial Fibrillation and remains terminated or withdrawn. Sponsored by Stony Brook University, it has been updated 6 times since 2019, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
May 2022 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3

Status: Unknown Status → Terminated
Oct 2021 — May 2022 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Sep 2019 — Jan 2021 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Aug 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stony Brook University

Data source: Stony Brook University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stony Brook, United States